Last reviewed · How we verify
Zymar (GATIFLOXACIN)
At a glance
| Generic name | GATIFLOXACIN |
|---|---|
| Sponsor | Allergan |
| Target | DNA gyrase, DNA gyrase, DNA gyrase subunit A |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2003 |
Approved indications
- Acute bacterial sinusitis
- Acute exacerbation of chronic bronchitis
- Acute gonococcal cervicitis
- Acute gonococcal urethritis
- Bacterial conjunctivitis
- Bacterial pneumonia
- Bacterial urinary infection
- Chlamydial pneumonia
- Complicated Proteus UTI
- E. Coli Pyelonephritis
- Escherichia coli urinary tract infection
- Gonorrhea of rectum
- Haemophilus Influenzae Chronic Bronchitis
- Haemophilus Parainfluenzae Chronic Bronchitis
- Haemophilus Parainfluenzae Pneumonia
- Haemophilus influenzae pneumonia
- Infection due to Staphylococcus aureus
- Klebsiella cystitis
- Legionella Pneumophila Pneumonia
- Moraxella Catarrhalis Chronic Bronchitis
Common side effects
- Worsening of conjunctivitis
- Eye irritation
- Dysgeusia
- Eye pain
- Chemosis
- Conjunctival hemorrhage
- Dry eye
- Eye discharge
- Eyelid edema
- Headache
- Increased lacrimation
- Keratitis
Key clinical trials
- A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study (PHASE4)
- Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients (PHASE4)
- Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen (PHASE4)
- Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. (PHASE3)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (PHASE3)
- Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zymar CI brief — competitive landscape report
- Zymar updates RSS · CI watch RSS